Two or Three? Clinical and Proteomic Perspectives on Dolutegravir/Lamivudine Versus Bictegravir/ Emtricitabine/Tenofovir Alafenamide as Initial HIV Treatment
While triple-drug regimens (3DR) have long been the standard of care for HIV infection, two-drug regimens (2DR), particularly dolutegravir/lamivudine (DTG/3TC), have emerged as viable first-line options. However, there is limited understanding of how baseline clinical profiles associated with regime...
| Autores: | , , , , , , , , , , |
|---|---|
| Tipo de recurso: | artículo |
| Fecha de publicación: | 2025 |
| País: | España |
| Institución: | Universidad Europea (UEM) |
| Repositorio: | ABACUS. Repositorio de Producción Científica |
| Idioma: | inglés |
| OAI Identifier: | oai:abacus.universidadeuropea.com:11268/16446 |
| Acceso en línea: | https://hdl.handle.net/11268/16446 |
| Access Level: | acceso abierto |
| Palabra clave: | Antirretrovirales Ciencias médicas Política de la salud Biotecnología Goal 3: Ensure healthy lives and promote well-being for all at all ages Goal 9: Build resilient infrastructure, promote sustainable industrialization and foster innovation |
| Sumario: | While triple-drug regimens (3DR) have long been the standard of care for HIV infection, two-drug regimens (2DR), particularly dolutegravir/lamivudine (DTG/3TC), have emerged as viable first-line options. However, there is limited understanding of how baseline clinical profiles associated with regimen choice relate to underlying inflammatory states and long-term immune trajectories. Regimen selection was associated with baseline disease severity and inflammatory burden. Despite being used in patients with more advanced profiles, BIC/F/TAF effectively reduced systemic inflammation over 2 years. Both regimens attenuated inflammatory activity, though with distinct trajectories that may carry implications for immune recovery and long-term outcomes. |
|---|